Celldex Therapeutics (CLDX) to Release Quarterly Earnings on Wednesday

Celldex Therapeutics (NASDAQ:CLDX) is anticipated to announce its Q3 2025 results before the market opens on Wednesday, November 5th. Analysts expect the company to announce earnings of ($0.88) per share and revenue of $1.12 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Monday, November 3, 2025 at 4:00 PM ET.

Celldex Therapeutics (NASDAQ:CLDX) last announced its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported ($0.85) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.86) by $0.01. The firm had revenue of $0.73 million for the quarter, compared to analysts’ expectations of $1.13 million. Celldex Therapeutics had a negative net margin of 3,446.88% and a negative return on equity of 27.61%. On average, analysts expect Celldex Therapeutics to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Celldex Therapeutics Stock Performance

Shares of Celldex Therapeutics stock opened at $27.06 on Wednesday. The firm has a fifty day moving average of $25.00 and a two-hundred day moving average of $22.37. The stock has a market capitalization of $1.80 billion, a price-to-earnings ratio of -8.99 and a beta of 1.33. Celldex Therapeutics has a 52 week low of $14.40 and a 52 week high of $29.05.

Institutional Trading of Celldex Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Russell Investments Group Ltd. lifted its holdings in Celldex Therapeutics by 27.6% during the 2nd quarter. Russell Investments Group Ltd. now owns 2,315 shares of the biopharmaceutical company’s stock valued at $47,000 after purchasing an additional 501 shares during the last quarter. Headlands Technologies LLC bought a new position in Celldex Therapeutics in the 2nd quarter valued at about $125,000. Tower Research Capital LLC TRC lifted its position in Celldex Therapeutics by 289.6% during the second quarter. Tower Research Capital LLC TRC now owns 7,247 shares of the biopharmaceutical company’s stock worth $147,000 after acquiring an additional 5,387 shares during the last quarter. Hsbc Holdings PLC bought a new stake in shares of Celldex Therapeutics during the second quarter worth approximately $347,000. Finally, Jump Financial LLC boosted its holdings in shares of Celldex Therapeutics by 53.3% during the second quarter. Jump Financial LLC now owns 29,503 shares of the biopharmaceutical company’s stock worth $600,000 after acquiring an additional 10,255 shares during the period.

Analysts Set New Price Targets

Several equities research analysts have issued reports on CLDX shares. Wells Fargo & Company lowered their price target on Celldex Therapeutics from $44.00 to $38.00 and set an “overweight” rating for the company in a report on Wednesday, August 20th. Citigroup lowered their target price on Celldex Therapeutics from $56.00 to $48.00 and set a “buy” rating for the company in a research note on Wednesday, August 20th. HC Wainwright cut their price target on shares of Celldex Therapeutics from $50.00 to $42.00 and set a “buy” rating on the stock in a research note on Wednesday, August 20th. Barclays initiated coverage on shares of Celldex Therapeutics in a report on Monday, October 13th. They issued an “underweight” rating and a $25.00 price target for the company. Finally, Canaccord Genuity Group restated a “buy” rating and set a $62.00 price objective on shares of Celldex Therapeutics in a report on Wednesday, September 17th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $44.20.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.